×

Register now for full access to all the content

First Name
Last Name
Company Name
Title
Country
Thank you for registering!
Error - something went wrong!

PAREXEL - Roland Andersson, SVP, Discusses Investing Trends and Emerging Biopharmaceutical Companies

May 18, 2015
PAREXEL helps position emerging Biopharmaceutical companies by providing them with advice and capabilities. We provide them with advice regarding clinical research strategies, regulatory strategies, as well as expedited approval pathways, to give a few examples. In terms of capabilities, we provide them with all capabilities required to successfully complete a clinical study, and this includes everything from clinical, regulatory, technology, logistics and a large number of additional capabilities. Biopharmaceutical companies will remain one of the major sources of innovation also in the future. For the large global pharmaceutical companies, this means that they will continue to partner and heavily invest in these clients to be able to acquire some or all of that innovation. From the perspective of a venture capital investor, this presents a very attractive opportunity. It includes risk, but the upside of getting - on having funded an approved drug on the market is enormous. When a global pharmaceutical company or an investor is evaluating a biotech company they are typically looking for innovation, IP, and quality. In terms of innovation, the company needs to have novel science, typically around a new disease target. IP is the ability to protect this innovation with patents, and quality involves both quality of the science as well as the quality of the execution of the clinical studies that, if successful, lead to drug approval. The investing trends we are seeing on the current Biopharm landscape include an increasing emphasis on oncology, which has been the largest area for the last 10 years. We are also seeing a lot of investment interest in autoimmune diseases. We are seeing targeted therapies, that is, pursuing sub-populations of larger disease areas such as cardiovascular disease being an additional area of interest, and finally a lot of interest in novel devices, either for drug delivery such as inhalation devices, as well as devices that are attributed to better patience adherence, i.e., that the patient is actually taking the drugs they are supposed to take.
Previous Video
PAREXEL - Albert Liou Discusses the Drug Development Landscape in Korea
PAREXEL - Albert Liou Discusses the Drug Development Landscape in Korea

Korea is becoming a global hub for many reasons. There is a good infrastructure, good regulatory system, an...

Next Video
PAREXEL - Mark A. Goldberg, Pres. & COO, Discusses PAREXEL’s Acquisition of Quantum Solutions India
PAREXEL - Mark A. Goldberg, Pres. & COO, Discusses PAREXEL’s Acquisition of Quantum Solutions India

I think the QSI acquisition is going to help benefit our clients. First of all, this is an up and running c...